Emergent BioSolutions Inc. (EBS) earnings
EBS earnings moved a median of 0.00% by the close. Quarterly and annual EBS reports and results, each read against the price at its own news timestamp. Back to the EBS overview →
35 measured EBS earnings events.
Where these EBS earnings landedvs 35 measured EBS earnings reactions
| Middle 50% of EBS earnings reactions | -4.77% to +9.45% |
|---|---|
| Median reaction (to close) | 0.00% |
| Measured reactions | 35 |
Point-in-time · zero look-ahead
Half of the 35 EBS earnings events with a measured close landed between -4.77% and +9.45%; 49% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Emergent BioSolutions For: Jun 30 | SEC filing · Form 10-Q | -1.22% | -7.65% | |
| Emergent BioSolutions Reports Second Quarter 2026 Financial Results | Press release | -1.22% | -7.65% | |
| Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026 | Press release | +0.80% | +0.00% | |
| Form 10-Q Emergent BioSolutions For: Mar 31 | SEC filing · Form 10-Q | -11.48% | -2.48% | |
| Emergent BioSolutions Reports First Quarter 2026 Financial Results | Press release | -5.39% | -5.78% | |
| Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026 | Press release | -0.11% | -1.01% | |
| Form 10-K Emergent BioSolutions For: Dec 31 | SEC filing · Form 10-K | +9.15% | -0.61% | |
| Form 10-Q Emergent BioSolutions For: Sep 30 | SEC filing · Form 10-Q | +12.13% | +16.73% | |
| Emergent BioSolutions Reports Third Quarter 2025 Financial Results | Press release | +12.13% | +16.73% | |
| Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025 | Press release | +0.60% | -0.50% | |
| Form 10-Q Emergent BioSolutions For: Jun 30 | SEC filing · Form 10-Q | +9.47% | +26.19% | |
| Emergent BioSolutions Reports Second Quarter 2025 Financial Results | Press release | +9.47% | +26.19% | |
| Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025 | Press release | -0.82% | -5.59% | |
| Form 10-Q Emergent BioSolutions For: Mar 31 | SEC filing · Form 10-Q | +1.32% | +15.64% | |
| Emergent BioSolutions Reports First Quarter 2025 Financial Results | Press release | +1.32% | +15.64% | |
| Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025 | Press release | +1.09% | +3.28% | |
| Form 10-K Emergent BioSolutions For: Dec 31 | SEC filing · Form 10-K | -5.04% | +11.13% | |
| Form 10-Q Emergent BioSolutions For: Sep 30 | SEC filing · Form 10-Q | +7.95% | -3.93% | |
| Emergent BioSolutions Reports Third Quarter 2024 Financial Results | Press release | +7.95% | -3.93% | |
| Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024 | Press release | +1.43% | -3.95% | |
| Form 10-Q Emergent BioSolutions For: Jun 30 | SEC filing · Form 10-Q | -8.50% | -9.92% | |
| Emergent BioSolutions Reports Second Quarter 2024 Financial Results | Press release | -8.50% | -9.92% | |
| Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024 | Press release | +1.83% | +8.89% | |
| Form 10-Q Emergent BioSolutions For: Mar 31 | SEC filing · Form 10-Q | -0.34% | +10.00% | |
| Emergent BioSolutions Reports First Quarter 2024 Financial Results | Press release | -0.34% | +10.00% | |
| Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024 | Press release | -0.49% | +5.88% | |
| Form 10-K Emergent BioSolutions For: Dec 31 | SEC filing · Form 10-K | +5.18% | +3.70% | |
| Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results | Press release | +1.31% | +3.36% | |
| Form 10-K/A Emergent BioSolutions For: Dec 31 | SEC filing · Form 10-K | -0.43% | -13.82% | |
| Form 10-Q Emergent BioSolutions For: Sep 30 | SEC filing · Form 10-Q | -0.43% | -13.82% | |
| Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing | Press release | +1.50% | +4.50% | |
| Form NT 10-Q Emergent BioSolutions For: Sep 30 | SEC filing · Form NT | -1.40% | -6.54% | |
| Emergent BioSolutions Reports Third Quarter 2023 Financial Results | Press release | -0.94% | +3.87% | |
| UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023 | Press release | +0.99% | +3.98% | |
| Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023 | Press release | -0.87% | -3.06% |
Keep exploring
More EBS: analyst actions → · SEC filings → · EBS overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Teleflex Incorporated (TFX) | 460 | -0.02% | 49% |
| CAS MEDICAL SYSTEMS (CASM) | 459 | 0.00% | 35% |
| REXAHN PHARMACEUTICALS (RNN) | 458 | -0.35% | 41% |
| NUVECTRA CORP COMMON (NVTR) | 456 | 0.00% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.